40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods

4DMedical caught bids this week and finished on top.

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Investors are bidding up the 4DMedical share price hard this week after a key announcement
  • The launch of the company's XV Scanner is a key driver to the commercialisation of its XV Technology strategy, it says
  • In the last 12 months, the 4DMedical share price has sunk by 44%

The 4DMedical Ltd (ASX: 4DX) share price climbed higher on Friday afternoon to close up 1.18% at 85.5 cents.

Investors appear to be rallying behind Thursday's announcement, which revealed the company is launching the world's first dedicated lung scanner.

The 4DMedical share price soared almost 20% yesterday. It's likely that momentum spilled over into today's session as trading volume surged well past its four-week average at 764,665 shares.

With big gains also on Tuesday and Wednesday, it means 4DMedical shares have surged 41% since last Friday's close. This week's gain is a welcome reprieve for 4D shareholders, who've seen their holdings evaporate over the past 12 months.

TradingView Chart

What's been happening at 4DMedical?

The company advised that it has installed the 'XV Scanner' at the Prince of Wales Hospital in Sydney after it was unveiled to the Federal health minister on Thursday.

4D says the scanner will provide unparalleled access to visually map the lung and provides "highly visual insight into lung function".

A successful launch will hopefully see the market adopt its XV Technology, something the company says is integral to successful commercialisation.

But the benefits extend primarily to the doctor-patient realm, and the scanner itself is considered somewhat a "breakthrough in innovation", according to Lung Foundation Australia CEO, Mark Brooke.

It's reported that seven million Australian currently are living with or are impacted by lung disease in some way, therefore any breakthrough would be a welcome sigh of relief to many.

Evans and Partners have 4DMedical rated as a speculative buy and value the company at $1.50 per share, suggesting an upside potential of 75% at the time of writing.

Meanwhile, Bell Potter has the company rated as a speculative hold but sets a price target of $2.07 per share — a mammoth 142% upside potential.

According to Bloomberg data, the consensus valuation is $1.78 per share, still a considerable amount of upside potential if the bull case plays out to that level.

4DMedical share price snapshot

In the last 12 months, the 4DMedical share price has sunk and is now 44% in the red. It is also down 36% this year to date.

Despite the 40% gain this week, shares have still fallen into the red by 5% over the past month.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »